PDCD1 and neoplasm: We found that this dosage of EGFRvIII CAR T alone had a modest impact on tumor size compared with PD1 blocking Ab treated UTD T cells, and conferred no improvement in overall survival (OS) per Kaplan-Meyer curve (median OS = 36d for UTD + PD1 Ab, 28d for CAR T alone).